替雷利珠单抗（抗TIGIT）用于小细胞肺癌：Skyscraper-02，一场熊熊大火。
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
作者信息
Brazel Danielle, Ou Sai-Hong Ignatius, Nagasaka Misako
机构信息
Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
Chao Family Comprehensive Cancer Center, Orange, CA, USA.
出版信息
Lung Cancer (Auckl). 2023 Jan 5;14:1-9. doi: 10.2147/LCTT.S379389. eCollection 2023.
Abstract
Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.
摘要
小细胞肺癌（SCLC）的特点是进展迅速且预后较差。尽管II期CITYSCAPE-02试验发现，在阿替利珠单抗和化疗中加入替雷戈珠单抗时，非小细胞肺癌（NSCLC）患者的客观缓解率（ORR）和无进展生存期（PFS）有所改善，但III期SKYSCRAPER-02试验未能发现替雷戈珠单抗对SCLC患者的PFS或总生存期（OS）有获益。根据III期IMpower133研究，阿替利珠单抗是首个在广泛期SCLC中显示出生存获益的免疫疗法。鉴于免疫疗法已成为SCLC患者的标准治疗方案，需要进一步研究增强免疫系统的方法，以更好地治疗这些患者。
相似文献
1
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
Lung Cancer (Auckl). 2023 Jan 5;14:1-9. doi: 10.2147/LCTT.S379389. eCollection 2023.
2
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.
3
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.
4
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study.
Med. 2024 Apr 12;5(4):281-284. doi: 10.1016/j.medj.2024.02.001.
5
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
J Thorac Oncol. 2022 Sep;17(9):1122-1129. doi: 10.1016/j.jtho.2022.05.016. Epub 2022 Jun 25.
6
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Thorac Cancer. 2022 Dec;13(23):3384-3392. doi: 10.1111/1759-7714.14697. Epub 2022 Oct 23.
7
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055. Epub 2021 Jan 13.
8
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
J Oncol. 2020 Sep 29;2020:2368164. doi: 10.1155/2020/2368164. eCollection 2020.
9
Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
Clin Lung Cancer. 2019 Nov;20(6):469-476.e1. doi: 10.1016/j.cllc.2019.07.005. Epub 2019 Jul 31.
10
Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Curr Treat Options Oncol. 2020 Jun 29;21(8):64. doi: 10.1007/s11864-020-00762-8.
引用本文的文献
1
Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors.
Mol Cancer. 2025 Aug 11;24(1):216. doi: 10.1186/s12943-025-02413-8.
2
Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy.
Front Pharmacol. 2025 Jun 11;16:1568664. doi: 10.3389/fphar.2025.1568664. eCollection 2025.
3
Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy.
NPJ Precis Oncol. 2025 May 15;9(1):142. doi: 10.1038/s41698-025-00933-6.
4
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer.
Cancer Res. 2025 Jul 15;85(14):2574-2590. doi: 10.1158/0008-5472.CAN-24-3844.
5
Promising New Anti-TIGIT Agents: Stealthy Allies in Cancer Immunotherapy.
Clin Transl Sci. 2025 Apr;18(4):e70212. doi: 10.1111/cts.70212.
6
A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma.
J Exp Clin Cancer Res. 2025 Feb 12;44(1):51. doi: 10.1186/s13046-025-03314-w.
7
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.
J Hematol Oncol. 2025 Jan 13;18(1):6. doi: 10.1186/s13045-024-01634-6.
8
Coordinated translational control of multiple immune checkpoints by the integrated stress response pathway in lung cancer.
bioRxiv. 2024 Oct 28:2024.10.23.619897. doi: 10.1101/2024.10.23.619897.
9
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
Thorac Cancer. 2024 May;15(15):1246-1262. doi: 10.1111/1759-7714.15310. Epub 2024 Apr 16.
10
Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness.
Pharmaceuticals (Basel). 2024 Mar 18;17(3):387. doi: 10.3390/ph17030387.
本文引用的文献
1
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13.
2
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21.
3
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
4
Tiragolumab Impresses in Multiple Trials.
Cancer Discov. 2020 Aug;10(8):1086-1087. doi: 10.1158/2159-8290.CD-NB2020-063. Epub 2020 Jun 23.
5
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.
6
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
J Immunother Cancer. 2019 Jun 25;7(1):160. doi: 10.1186/s40425-019-0634-9.
7
CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration.
Life Sci. 2019 Aug 15;231:116543. doi: 10.1016/j.lfs.2019.116543. Epub 2019 Jun 6.
8
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Oncol Lett. 2019 Mar;17(3):2960-2968. doi: 10.3892/ol.2019.9910. Epub 2019 Jan 9.
9
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 T-cell Function.
Cancer Immunol Res. 2019 Feb;7(2):257-268. doi: 10.1158/2326-6066.CIR-18-0442. Epub 2019 Jan 18.
10
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
Zotero 插件